- Home
- WDH vs AMRN Comparison
WDH vs AMRN Comparison
Compare WDH & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDH | AMRN |
|---|---|---|
| Founded | 2016 | 1989 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.8M | 342.8M |
| IPO Year | 2020 | 1998 |
Fundamental Metrics
Financial Performance| Metric | WDH | AMRN |
|---|---|---|
| Price | $1.12 | $14.29 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 120.2K | 59.2K |
| Earning Date | 06-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.71 | $1.26 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $1.08 | $12.96 |
| 52 Week High | $2.18 | $20.90 |
Technical Indicators
Market Signals| Indicator | WDH | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 42.77 |
| Support Level | $1.10 | $13.47 |
| Resistance Level | $1.22 | $14.49 |
| Average True Range (ATR) | 0.04 | 0.48 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 7.61 | 50.00 |
Price Performance
Historical ComparisonAbout WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. The Company is mainly engaged in operating an independent third-party insurance platform dedicated to providing insurance and healthcare service. The Companies main businesses are the insurance marketplace, medical crowdfunding, and mutual aid. The companies reportable segments are Insurance, Crowdfunding and Others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.